{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:15:24Z","timestamp":1761178524598,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.canrad.2018.07.131","type":"journal-article","created":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T10:07:35Z","timestamp":1535796455000},"page":"509-514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer du canal anal\u00a0: \u00e0 l\u2019\u00e8re de la radioth\u00e9rapie conformationnelle avec modulation d\u2019intensit\u00e9, questions en suspens"],"prefix":"10.1016","volume":"22","author":[{"given":"D.","family":"Peiffert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"Serre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Rouard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Vogin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2018.07.131_bib0005","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Glynne-Jones","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2018.07.131_bib0015","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0020","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.canrad.2018.07.131_bib0025","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/j.canrad.2016.07.061","article-title":"Radioth\u00e9rapie des cancers du canal anal","volume":"20","author":"Peiffert","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.07.131_bib0030","doi-asserted-by":"crossref","first-page":"e1288331","DOI":"10.1080\/2162402X.2017.1288331","article-title":"Human papilloma virus load and PD-1\/PD-L1, CD8(+) and FOXP3\u00a0in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy","volume":"6","author":"Balermpas","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canrad.2018.07.131_bib0035","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JCO.2017.74.9291","article-title":"Anal cancer risk among people with HIV infection in the United States","volume":"36","author":"Colon-Lopez","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0040","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jamaoncol.2017.0115","article-title":"Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy","volume":"3","author":"Yanik","year":"2017","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.canrad.2018.07.131_bib0045","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1245\/s10434-015-4391-9","article-title":"The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis","volume":"22","author":"Jones","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0050","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(17)30456-4","article-title":"Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study","volume":"18","author":"Sekhar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0055","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1007\/s00330-017-5133-0","article-title":"The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal","volume":"28","author":"Prezzi","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0060","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.ejrad.2016.05.009","article-title":"Metabolic tumour volume of anal carcinoma on (18F)-FDG PET\/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival","volume":"85","author":"Mohammadkhani Shali","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0065","first-page":"26","article-title":"Evaluation by (18F)-FDG-PET of patients with anal squamous cell carcinoma","volume":"12","author":"Iagaru","year":"2009","journal-title":"Hell J Nucl Med"},{"key":"10.1016\/j.canrad.2018.07.131_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2018.04.062","article-title":"Association of interim FDG-PET imaging during chemoradiation for squamous anal canal carcinoma with recurrence","author":"Hong","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.131_bib0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/DCR.0000000000000291","article-title":"Does endoscopic ultrasound improve detection of locally recurrent anal squamous-cell cancer?","volume":"58","author":"Peterson","year":"2015","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.canrad.2018.07.131_bib0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2\u00a0evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.131_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.canrad.2018.07.028","article-title":"Radioth\u00e9rapie conformationnelle avec modulation d\u2019intensit\u00e9 des cancers du canal anal\u00a0: impact de la d\u00e9lin\u00e9ation sur le risque de r\u00e9cidive","volume":"22","author":"Rouard","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.07.131_bib0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.radonc.2008.04.011","article-title":"The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer","volume":"87","author":"Saarilahti","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0095","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/COC.0000000000000009","article-title":"Intensity-modulated radiation therapy for anal cancer: results from a multi-institutional retrospective cohort study","volume":"39","author":"Call","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0100","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2018.07.131_bib0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.adro.2017.01.009","article-title":"Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529","volume":"2","author":"Mitra","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0110","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.clon.2015.08.006","article-title":"Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3\u00a0year outcomes at two Sydney institutions","volume":"27","author":"Yates","year":"2015","journal-title":"Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.131_bib0120","first-page":"39","article-title":"Intensity-modulated radiation therapy vs. 3d conformal radiation therapy for squamous cell carcinoma of the anal canal","volume":"6","author":"Chuong","year":"2013","journal-title":"Gastrointes Cancer Res"},{"key":"10.1016\/j.canrad.2018.07.131_bib0125","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2007.12.0170","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience","volume":"25","author":"Salama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.clon.2011.09.014","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma--clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network","volume":"24","author":"DeFoe","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1748-717X-7-45","article-title":"IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center","volume":"7","author":"Vieillot","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/COC.0b013e31827e52a3","article-title":"Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity","volume":"37","author":"Mitchell","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0145","doi-asserted-by":"crossref","first-page":"10688","DOI":"10.3748\/wjg.v21.i37.10688","article-title":"Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16\u00a0positivity","volume":"21","author":"Belgioia","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0150","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/07357907.2015.1028586","article-title":"Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series","volume":"33","author":"Franco","year":"2015","journal-title":"Cancer Invest"},{"key":"10.1016\/j.canrad.2018.07.131_bib0155","first-page":"1943","article-title":"Early-stage node-negative (T1-T2N0) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy","volume":"36","author":"Franco","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2018.07.131_bib0160","first-page":"2027","article-title":"Locally advanced (T3-T4\u00a0or N+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy","volume":"36","author":"Franco","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.canrad.2018.07.131_bib0165","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3109\/0284186X.2015.1124141","article-title":"Clinical outcome in patients treated with simultaneous integrated boost - intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal","volume":"55","author":"Tomasoa","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1748-717X-7-201","article-title":"Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?","volume":"7","author":"Dewas","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0175","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/02841860600726729","article-title":"Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome","volume":"45","author":"Meyer","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0180","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","article-title":"Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16\u00a0phase II trial","volume":"24","author":"Deutsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0185","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03\u00a0trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0190","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.canrad.2016.08.119","article-title":"Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2\u00a0and ACCORD 03)","volume":"20","author":"Faivre","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.07.131_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.canrad.2018.06.004","article-title":"Radioth\u00e9rapie des cancers du rectum: strat\u00e9gie th\u00e9rapeutique et perspective","volume":"22","author":"Vendrely","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.07.131_bib0200","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3857\/roj.2017.00227","article-title":"Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma","volume":"35","author":"Sakanaka","year":"2017","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.canrad.2018.07.131_bib0205","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2009.09.029","article-title":"Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning","volume":"78","author":"Wright","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.131_bib0210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clon.2012.08.008","article-title":"Organ-sparing intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans","volume":"25","author":"Brooks","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.radonc.2013.03.012","article-title":"Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis","volume":"107","author":"Dasgupta","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2018.07.131_bib0220","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ijrobp.2006.12.052","article-title":"Predictors and patterns of recurrence after definitive chemoradiation for anal cancer","volume":"68","author":"Das","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.07.131_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.canrad.2018.06.019","article-title":"Apport du guidage par l\u2019image et du repositionnement du patient pour la radioth\u00e9rapie du cancer anorectal","volume":"22","author":"Masson","year":"2018","journal-title":"Cancer Radiother"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818302865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818302865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:30:09Z","timestamp":1761136209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321818302865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":45,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1278321818302865"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2018.07.131","relation":{},"ISSN":["1278-3218"],"issn-type":[{"type":"print","value":"1278-3218"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer du canal anal\u00a0: \u00e0 l\u2019\u00e8re de la radioth\u00e9rapie conformationnelle avec modulation d\u2019intensit\u00e9, questions en suspens","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2018.07.131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}